Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea Starts Onsite Inspections Of Essential Drug Reserves Amid Tension With North Korea

This article was originally published in PharmAsia News

Executive Summary

As tensions between South and North Korea simmer, South Korea is conducting its first on-site inspections of drug reserves since 2006.

You may also be interested in...



South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax

SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S

South Korean Government To Build New Flu Vaccine Plant As Part Of Campaign For "Vaccine Independence" From Global Giants

SEOUL - To avoid a recurrence of last year's challenge to secure flu vaccines during the A/H1N1 pandemic, South Korea's government has initiated a drive to bolster the nation's independent capacity to produce these vaccines

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel